tbuckley/cabot-search huggingface dataset:
Abstract 5714: Influence of Body Mass Index on Early Diastolic Untwisting Velocity in Healthy Children
Authors: Christine O’Reilly, Katrina Abhayaratna, Satoru Sakuragi, Richard Telford, Walter P Abhayaratna
Journal: Circulation (2008)

Background: Childhood obesity is increasingly prevalent in the community and is predictive of adverse cardiovascular outcomes in adulthood. We hypothesised that increased body mass index (BMI) in children has an adverse influence on left ventricular (LV) untwisting, a sensitive marker of LV function that reflects a key process in the transition between LV relaxation and suction. Methods: Cardiac structure and function were assessed by transthoracic echocardiography. LV twist mechanics were quantitated using 2-dimensional speckle tracking imaging of the LV base and apex in short axis. Univariate associations of LV untwisting velocity (Er) were evaluated using Spearman’s correlation analysis. Significant univariate predictors (p≤0.10) were included into multivariable regression analysis to determine the independent relationship between body mass and Er (rad/s). Results: Of the first 150 children assessed (age 10.2 ± 0.3 years; 83 boys), the mean BMI was 18.2 ± 2.8 kg/m 2 . In univariate analysis, Er was inversely related to BMI (ρ= −0.13, p=0.10), LV end-diastolic diameter (ρ= −0.13, p=0.10) and LV end-systolic diameter (ρ= −0.28, p&lt;0.001); and positively correlated with LV torsion (ρ=0.55, p&lt;0.001), LV twisting velocity (ρ=0.29, p&lt;0.001), early diastolic annular velocity (e′) (ρ=0.13, p=0.10), LV ejection fraction (EF) (ρ=0.14, p=0.09) and heart rate (ρ=0.18, p=0.03). There was no correlation between Er and LV relative wall thickness or mass index (p&gt;0.25). In multivariable analysis, body mass index was independently associated with Er, independent of LV torsion, heart rate, EF, LV chamber size and e′ (Table ). Conclusion: Increased body mass is independently related to lower LV untwisting velocity during early diastole in healthy children. Additional studies are required to evaluate whether lifestyle measures to reduce body mass will attenuate further deterioration in LV diastolic relaxation and suction. Table: Independent Predictors of Left Ventricular Untwisting Velocity in Children
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol
Authors: Karina Berg, Emina Hadzalic, Inger Gjertsen, Vegard Forsaa, Lars Haakon Berger, Bettina Kinge, Hans Henschien, Kristian Fossen, Slavica Markovic, Terje R Pedersen, Leiv Sandvik, Ragnheiður Bragadóttir
Journal: Ophthalmology (2015)
Abstract 1478: Angiogenesis After a Myocardial Infarction is Regulated by Bone Marrow c-kit+ Cells
Authors: Shafie Fazel, Massimo Cimini, Liwen Chen, Shu-Hong Li, Denis Angoulvant, Paul Fedak, Subodh Verma, Richard D Weisel, Armand Keating, Ren-Ke Li
Journal: Circulation (2006)

Introduction: Clinical trials of bone marrow stem cell therapy after myocardial infarction (MI) have shown promising results, but the mechanism for the benefit is unclear. We examined the endogenou...
PSYCHIATRIC CASUALTIES AMONG DEFENSE WORKERS
Authors: MILTON ROSENBAUM, JOHN ROMANO
Journal: American Journal of Psychiatry (1943)

The working efficiency of the defense worker is as important to the successful prosecution of the war as the fighting efficiency of the soldier or sailor. Impaired efficiency in industry may be caused, provoked or modified by physical illness. The researches and long range plans of industrial medicine, particularly as they have been developed in the larger industries have been of inestimable and permanent value. These have included the establishment of educational programs concerning safety methods and devices, maintenance of first aid and medical clinics in the factories, recognition and control of the variables of heat, light, ventilation, nutrition and fatigue. For the most part such efforts have been directed towards safety and the physical health of the worker. Emotional factors however may act to cause, provoke or modify behavior so as to impair efficiency. This is not always recognized by the industrial physician.2 The emotional distress may be expressed in the form of impersonal or somatic symptoms, such as fatigue, listlessness or epigastric distress; in personal or psychologic symptoms such as a phobia or hysterical behavior; in interpersonal symptoms such as feelings of discrimination or depreciation toward his fellow employees or employers. From the industrial point of view, such expressions of emotional distress are important in terms of inferior output, high sick-
Celebrating the ACP Centennial: From the <i>Annals</i> Archive—Non-A, Non-B Hepatitis
Authors: Deborah Cotton
Journal: Annals of Internal Medicine (2015)

Editorials18 August 2015Celebrating the ACP Centennial: From the Annals Archive—Non-A, Non-B HepatitisDeborah Cotton, MD, MPHDeborah Cotton, MD, MPHSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-1300 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail During the 2015 centennial year of the American College of Physicians, publisher of Annals of Internal Medicine, Annals editors will link an article in each issue with an earlier paper from our archives addressing the same disease or clinical question. We hope our readers find this interesting and we welcome comments, especially from physicians who were practicing at the time of publication of the original paper who might offer insight into the impact of the earlier paper on their knowledge or practice.In this issue, Onofrey and colleagues (1) present evidence about current underascertainment of acute hepatitis C infection in ...References1. Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria A, ,Lauer GM, et al. Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system. A case series and chart review. Ann Intern Med. 2015;163:254-61. doi:10.7326/M14-2939 LinkGoogle Scholar2. Hoofnagle JH, Gerety RJ, Tabor E, Feinstone SM, Barker LF, Purcell RH. Transmission of non-A, non-B hepatitis. Ann Intern Med. 1977;87:14-20. [PMID: 195505] doi:10.7326/0003-4819-87-1-14 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTransmission of Non-A, Non-B Hepatitis JAY H. HOOFNAGLE , ROBERT J. GERETY , EDWARD TABOR , STEPHEN M. FEINSTONE , LEWELLYS F. BARKER , and ROBERT H. PURCELL Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System Shauna Onofrey , Jasneet Aneja , Gillian A. Haney , Ellen H. Nagami , Alfred DeMaria Jr. , Georg M. Lauer , Kelsey Hills-Evans , Kerri Barton , Stephanie Kulaga , Melinda J. Bowen , Noelle Cocoros , Barbara H. McGovern , Daniel R. Church , and Arthur Y. Kim Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System Shauna Onofrey , Jasneet Aneja , Gillian A. Haney , Ellen H. Nagami , Alfred DeMaria Jr. , Georg M. Lauer , Kelsey Hills-Evans , Kerri Barton , Stephanie Kulaga , Melinda J. Bowen , Noelle Cocoros , Barbara H. McGovern , Daniel R. Church , and Arthur Y. Kim Metrics 18 August 2015Volume 163, Issue 4Page: 315KeywordsArchivesBlood donorsClinical epidemiologyHepatitisHepatitis AHepatitis A virusHepatitis BHepatitis C virusLiver diseasesLiver function tests ePublished: 18 August 2015 Issue Published: 18 August 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
Authors: Manuela Terranova-Barberio, Elena DI Gennaro, Maria Roca, Alfredo Budillon
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Capecitabine, commonly used in different settings for metastatic breast cancer, is an inactive prodrug that take advantage of the tumor elevated levels of thymidine phosphorylase (TP), a key enzyme for its conversion to 5-florouracil. Potentiation of anticancer activity of
Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
Authors: David M. Brown, Quan Dong Nguyen, Dennis M. Marcus, David S. Boyer, Sunil Patel, Leonard Feiner, Patricio G. Schlottmann, Amy Chen Rundle, Jiameng Zhang, Roman G. Rubio, Anthony P. Adamis, Jason S. Ehrlich, J. Jill Hopkins
Journal: Ophthalmology (2013)

To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of ranibizumab in diabetic macular edema (DME).Phase III, randomized, multicenter, double-masked, 3-year trials, sham injection-controlled for 2 years.Adults with DME (n=759), baseline best-corrected visual acuity (BCVA) 20/40 to 20/320 Snellen equivalent, and central foveal thickness (CFT) ≥ 275 μm on optical coherence tomography.Patients were randomized equally (1 eye per patient) to monthly 0.5 mg or 0.3 mg ranibizumab or sham injection. In the third year, sham patients, while still masked, were eligible to cross over to monthly 0.5 mg ranibizumab. Macular laser was available to all patients starting at month 3; panretinal laser was available as necessary.The proportion of patients gaining ≥15 Early Treatment Diabetic Retinopathy Study letters in BCVA from baseline at month 24.Visual acuity (VA) outcomes seen at month 24 in ranibizumab groups were consistent through month 36; the proportions of patients who gained ≥15 letters from baseline at month 36 in the sham/0.5 mg, 0.3 mg, and 0.5 mg ranibizumab groups were 19.2%, 36.8%, and 40.2%, respectively, in RIDE and 22.0%, 51.2%, and 41.6%, respectively, in RISE. In the ranibizumab arms, reductions in CFT seen at 24 months were, on average, sustained through month 36. After crossover to 1 year of treatment with ranibizumab, average VA gains in the sham/0.5 mg group were lower compared with gains seen in the ranibizumab patients after 1 year of treatment (2.8 vs. 10.6 and 11.1 letters). Per-injection rates of endophthalmitis remained low over time (∼0.06% per injection). The incidence of serious adverse events potentially related to systemic vascular endothelial growth factor inhibition was 19.7% in patients who received 0.5 mg ranibizumab compared with 16.8% in the 0.3 mg group.The strong VA gains and improvement in retinal anatomy achieved with ranibizumab at month 24 were sustained through month 36. Delayed treatment in patients receiving sham treatment did not seem to result in the same extent of VA improvement observed in patients originally randomized to ranibizumab. Ocular and systemic safety was generally consistent with the results seen at month 24.Proprietary or commercial disclosure may be found after the references.
Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma
Authors: Parkash S. Gill, Anil Tulpule, Byron M. Espina, Suzanne Cabriales, Jocelyn Bresnahan, Miki Ilaw, Stan Louie, Nancy F. Gustafson, Marilyn A. Brown, Christopher Orcutt, Benjamin Winograd, David T. Scadden
Journal: Journal of Clinical Oncology (1999)

PURPOSE: Liposomal anthracyclines are the present standard treatment for advanced AIDS-related Kaposi's sarcoma (KS). No effective therapies have been defined for use after treatment failure of these agents. A phase II trial was thus conducted with paclitaxel in patients with advanced KS to assess safety and antitumor activity. MATERIALS AND METHODS: A regimen of paclitaxel at a dose of 100 mg/m 2 was given every 2 weeks to patients with advanced AIDS-related KS. Patients were treated until complete remission, disease progression, or unacceptable toxicity occurred. RESULTS: Fifty-six patients with advanced AIDS-related KS were accrued. Tumor-associated edema was present in 70% of patients and visceral involvement in 45%. Forty patients (71%) had received prior systemic therapy; 31 of these were resistant to an anthracycline. The median entry CD4 + lymphocyte count was 20 cells/mm 3 (range, 0 to 358). A median of 10 cycles (range, 1 to 54+) of paclitaxel was administered. Fifty-nine percent of patients showed complete (n = 1) or partial response (n = 32) to paclitaxel. The median duration of response was 10.4 months (range, 2.8 to 26.7+ months) and the median survival was 15.4 months. The main side effects of therapy were grade 3 or 4 neutropenia in 61% of patients and mild-to-moderate alopecia in 87%. CONCLUSION: Paclitaxel at 100 mg/m 2 given every 2 weeks is active and well tolerated in the treatment of advanced and previously treated AIDS-related KS. The median duration of response is among the longest observed for any regimen or single agent reported for AIDS-related KS. Paclitaxel at this dosage and schedule is a treatment option for patients with advanced AIDS-related KS, including those who have experienced treatment failure of prior systemic therapy.
Behavioral and economic approaches to decision making: A common ground
Authors: Edmund Fantino, Stephanie Stolarz-Fantino
Journal: Behavioral and Brain Sciences (2001)

Experimental psychologists in the learning tradition stress the importance of three of the authors' four key variables of experimental design. We review research investigating the roles played by these variables in studies of choice from our laboratory. Supporting the authors' claims, these studies show that the effects of these variables are not fixed and should not be taken for granted.
A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Authors: B G Redman, L Flaherty, T H Chou, A al-Katib, M Kraut, S Martino, B Chen, J Kaplan, M Valdivieso
Journal: Journal of Clinical Oncology (1990)

Twenty-six patients with metastatic cancer were entered into a phase I trial of concurrent recombinant interleukin-2 (IL-2) and recombinant interferon-gamma (IFN-gamma). IL-2 was administered as a continuous intravenous infusion for 5 days. IFN-gamma was administered by a daily intramuscular (IM) injection during the 5 days of IL-2 administration. Treatment was repeated twice after 9-day rest periods. After a 2-week rest, patients without evidence of tumor progression were retreated. Natural killer (NK)- and lymphokine-activated killer (LAK)-cell activity were assayed in each patient before treatment, on day 1, and on day 5 of each cycle. Constitutional symptoms occurred in most patients but were not dose-limiting. Other toxicities included hypotension responsive to fluids, transient elevations in liver function tests, erythema/pruritus, eosinophilia, and transient leukopenia/thrombocytopenia. The maximum-tolerated dose (MTD) of the combination was 1 x 10(6) U/m2/d of IL-2 combined with 0.50 mg/m2/d of IFN-gamma. The dose-limiting toxicity was pulmonary manifesting as rales and shortness of breath. The dose of the combination that resulted in the optimal generation of in vivo LAK-cell activity was a dose of at least 0.25 mg/m2/d of IFN-gamma combined with 1 x 10(6) U/m2/d of IL-2. Objective clinical responses were seen in five of 26 patients. These included a partial response of 2 months duration in a patient with non-Hodgkin's lymphoma (NHL), mixed responses in a patient with NHL and two patients with renal cell carcinoma (RCC), and an ongoing assessable response in a patient with bone metastases from RCC. The recommended dose for phase II trials of this combination is 0.50 mg/m2 of IFN-gamma and 1 x 10(6) U of IL-2.
Looking through the retrospectoscope in the era of evidence-based medicine.
Authors: E Shaw
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.4.1289 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9193318 Looking through the retrospectoscope in the era of evidence-based medicine. E ShawxE ShawSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.4.1289 PDF "Looking through the retrospectoscope in the era of evidence-based medicine.." Journal of Clinical Oncology, 15(4), pp. 1289–1290© 1997 by American Society of Clinical Oncology
Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction
Authors: Matthias Nahrendorf, Kai Hu, Karl-Heinz Hiller, Paolo Galuppo, Daniela Fraccarollo, German Schweizer, Axel Haase, Georg Ertl, Wolfgang R Bauer, Johann Bauersachs
Journal: Journal of the American College of Cardiology (2002)
Neorickettsia helminthoeca in Brazilian dogs: a cytopathological, histopathological and immunohistochemical study
Authors: S.A. Headley, F.S. Kano, D.G. Scorpio, K. Tamekuni, N.C. Barat, A.P.F.R.L. Bracarense, O. Vidotto, J.S. Dumler
Journal: Clinical Microbiology and Infection (2009)
Implementation of clinical triggers for palliative care consultation on a gynecologic oncology inpatient service: A pilot study.
Authors: Carolyn Lefkowits, Madeleine Courtney-Brooks, Winifred Teuteberg, Janet Leahy, Paniti Sukumvanich, Joseph L Kelley
Journal: Journal of Clinical Oncology (2014)

51 Background: Our objectives were to (1) Assess the feasibility of creating clinical triggers for Palliative Care (PC) consultation on a large gynecologic oncology service and (2) Use triggers to increase PC consultation rates among trigger positive patients. Methods: Clinical triggers for PC consultation are listed below. Over a six month period, patients meeting triggers were prospectively identified and PC consultation was requested for those patients. Retrospective chart review was used to identify patients meeting triggers and gather clinical information. PC consultation rates were compared for patients meeting triggers in the 6 months pre and post trigger implementation. Statistical analysis utilized χ 2 test, Fisher’s exact test and independent samples t-tests. Results: There was no difference in PC consultation rates among patients meeting triggers between the pre and post-triggers periods (see table). There was also no change in time from admission to PC consult (median time to PC consultation 1.56d vs. 2.24d, p=0.28) and no change in overall PC consultation volume (mean 17.3 new PC consults per 100 admissions/month vs. 18.5, p=0.67). Of the 38 patients in the post-triggers period who were not seen by PC, 50% (n=19) were inaccurately deemed trigger negative during their admission and 13% (n=5) were not screened at all. Conclusions: Creation of clinical triggers for PC consultation was feasible in terms of investment from relevant stakeholders. Trigger implementation was not associated with increased rates of PC consultation for those patients. High baseline rates of PC consultation and screening process issues contributed significantly to the lack of change in PC consultation rates. Use of clinical triggers may still hold promise as a strategy for standardizing PC consultation patterns and capturing subgroups of patients with high needs. Next steps include modifying our clinical triggers and screening process and expanding into the outpatient setting. [Table: see text]
Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets.
Authors: Lorie Ellis, Marie-Helene Lafeuille, Laurence Gozalo, Patrick Lefebvre, Elisabetta Malangone-Monaco, Kathleen Wilson, Kathleen A. Foley, R. Scott McKenzie
Journal: Journal of Clinical Oncology (2015)

228 Background: Little information exists regarding the sequences in which new mCRPC therapies with evidence of survival benefits are used. This study aims at describing the sequence of mCRPC medication use as observed in 3 healthcare datasets. Methods: Healthcare claims datasets (Dataset #1 and #2) and a community oncology electronic medical record (Dataset #3) were used to identify PC patients with ≥ 1 claim for a study drug (abiraterone acetate--AA, cabazitaxel--CAB, docetaxel – DOC, enzalutamide – ENZ, and sipuleucel T – SIP) occurring after 9/1/2012. The index date was the 1st study drug claim. Patients were excluded if a study drug claim occurred prior to 9/1/2012. Descriptive statistics summarized the proportion of patients receiving one vs. two or more lines of therapy. The prevalence of 1st line therapy and of 1st to 2nd-line sequences was analyzed. Results: Analysis of 3 unique datasets with &gt; 5,900 PC patients revealed most patients received a single line of therapy. AA and DOC were the most common 1st line agents. The five most-prevalent 1st- to 2nd-line sequences identified in each database are shown in the table below. The most commonly observed 1st- to 2nd-line sequences were AA-ENZ, AA-DOC, and DOC-AA. Conclusions: Real world treatment selection for 5 mCRPC medications was consistent across 3 datasets. The majority of PC patients had a prescription/claim for a single agent. AA and DOC were the most commonly selected 1 st line treatments. A 2nd-line agent was observed in 14-33% of patients. Similar patterns of 1st-2nd line sequences were observed between datasets. Further research is warranted with longer follow-up and consideration of other treatment interventions. [Table: see text]
Therapeutic outcomes for cavitary Mycobacterium avium complex (MAC) lung disease
Authors: David Griffith, Barbara Brown-Elliott, Sara Shepherd, Julie Philley, Richard Wallace
Journal: European Respiratory Journal (2012)

Beginning in 1992, patients were enrolled in a series of prospective clinical trials investigating the safety and efficacy of 3 or 4 drug macrolide-containing regimens for treating cavitary MAC lung disease. Based on these studies subsequent MAC lung disease patients received similar regimens. All patients were diagnosed according to contemporary nontuberculous mycobacterial (NTM) diagnostic guidelines. Patients are included in this analayis only if they had a macrolide susceptible MAC isolate prior to initiation of therapy and subsequently tolerated a 3 to 4 drug regimen consisting of macrolide, ethambutol, and a rifamyicn (rifampin or rifabutin) ± injectable agent (streptomycin or amikacin) administered daily or three times weekly. There were 240 patients in the intent to treat analysis with a mean age 63.2 ± 12.4 years (range 35-90 years) who were 76% male, 80% white and 75% current or exsmokers (≥ 10 pack years smoking). 134 patients had adequate records available for treatment outcome evaluation. 86/134 (64%) had sputum AFB culture conversion while on therapy. Over the study period, the all cause mortality was 57% for the intent to treat cohort and 41% for patients with sputum AFB culture conversion on therapy. We conclude that cavitary MAC lung disease can be effectively treated with macrolide-based regimens but is associated with high all cause mortality regardless of MAC treatment response.  Funded in part by the Amon Carter Foundation, Ft. Worth, TX and W.A. and E.B. Moncrief Distinguished Professorship UTHSCT.